SARS-CoV-2 Spike Glycoprotein RDB mRNA, United Kingdom Variant

Cat #: EG-339

Qty   
Product Name SARS-CoV-2 Spike Glycoprotein RBD mRNA, United Kingdom Variant
Description

This modified mRNA encodes the United Kingdom variant of the spike glycoprotein receptor binding domain (RBD, Arg319-Phe541) from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). This RBD mutant has N501Y mutation in the S glycoprotein RBD as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416).

Features
  • 5' Cap: Capped with ARCA (Anti Reverse Cap Analog, m7(3'-O-methyl)-G(5')ppp(5')G, Cap 0) or CleanCap AG (m7G(5')ppp(5')(2'OMeA)pG, Cap 1)
  • 5’-UTR: derived from human alpha-globin RNA with an optimized Kozak sequence
  • Codon Optimization: Human
  • Mutation: N501Y
  • Nucleotide Modifications: mRNA modified with both Pseudo-UTP and 5mCTP
  • 3’-UTR: comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA to confer RNA stability and high total protein expression.
  • PolyA: 180 nt
Sequence Available upon request.
Application Animal Vaccine Research (Not for human use)
Concentration ~1 μg/μl
Transfection Protocol Lipofectamine™ MessengerMAX™ Transfection Reagent Protocol
QC Agarose gel electrophoresis
Shipping Dry ice
Storage -80 oC